RECEIVED CENTRAL FAX CENTER JUN 14 2011

PTC/SB/81 (01-09)
Approved for use through 11/30/2011. OMB 0651-0035
U.S. Patent and Trad emark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no per	sons are required to resp	ond to a co	dection o	of Information	unless it dispi	ays a valid OMB cor	ntrol number	
DAMED OF A PRODUCT			Application Number			See attached Schedule A		
POWER OF ATTORNEY		Filing Date		See attached Schedule A				
OR		First Named Inventor		See attached Schedule A				
REVOCATION OF POWER OF ATTORNEY WITH A NEW POWER OF ATTORNEY			See	attached	d Schedul	e A		
AND		Titte See attache			See attached Schedule A			
CHANGE OF CORRESPONDENCE ADDRESS		Examiner Name		See attached Schedule A				
S. F. T. O. C.		Attorney Docket No.		See attached Schedule A				
I hereby revoke all previous powers of attorney given in the above-identified application.								
A Power of Attorney is submitted he	erewith.							
I hereby appoint Practitioner(s) associated with the following Number as my/our attorney(s) or agent(s) to prosecute the alidentified above, and to transact all business in the United St and Trademark Office connected therewith: OR		ppsication		23483				
I hereby appoint Practitioner(s) named below as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith:								
Practitioner(s) Name	Registration Number		Practitioner(s) Na			Registration Number]	
							1	
	:						•	
1 1							1	
Please recognize or change the correspond	ondence address	or the at	bove-i	dentified :	application	to:	4	
Please recognize or change the correspondence address for the above-identified application to: X The address associated with the above-mentioned Customer Number.								
OR								
The address associated with Customer Number.]				
OR								
Firm or Individual Name								
Address								
City	State			Zip				
Country	Telephone			Email				
I am the:		-						
Applicant/Inventor.								
	rest See 37 CFR	3 71						
Statement under 37 CFR 3-73(b) (F)			l herev	vith or file	d on			
Sight	TURE of Applicant	or Assig	nee o	Record				
Signature	کسر			Date		June 6,2011		
Name Richard Bagley			1	Telephon	ne 617-259-1970		0	
Title and Company President, COC CFO , ZIOPHARM Oncology, Inc.								
NOTE: Signatures of all the Inventors or assigned forms if more than one signature is required, see	s of record of the enti	re interest	or the					
X *Total of 1 forms are submitted.								

(

PTO/SB/96 (07-09)

Approved for use through 07/31/2012. OMB 0851-0031

U.S. Patent and Trad emark Office; U.S. DEPARTMENT OF COMMERC E

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unlass it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)							
Applicant/Patent Owner: See Attached Schedule A							
Application No./Patent No.: See Attached Schedule A Filed/issue Date: See Attached Schedule A							
Titled: Isophosphoramide Mustard Analogs and Use Thereof							
ZIOPHARM Oncology, Inc. , a Corporation							
(Name of Assignae) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)							
states that it is:							
1. x the assignee of the entire right, title, and interest in;							
2. an assignee of less than the entire right, title, and interest in							
(The extent (by percentage) of its ownership interest is %); or							
3. an assignee of an undivided interest in the entirety of (a complete assignment from one of the joint inventors was made)							
the patent application/patent identified above by virtue of either:							
A. An assignment from the inventor(s) of the patent application/patent identified above. The assignment was							
recorded in the United States Patent and Trademark Office at Reel							
Frame, or for which a copy thereof is attached. OR							
B X A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follow							
See Attached Schedule A To: See Attached Schedule A							
The document was recorded in the United States Patent and Trademark Office at							
Reel <u>Schedule a</u> , Frame <u>Schedule a</u> , or for which a copy thereof is attached.							
2. From: See Attached Schedule A To: See Attached Schedule A							
The document was recorded in the United States Patent and Trademark Office at							
Reel <u>Schedule a</u> , Frame <u>Schedule a</u> , or for which a copy thereof is attached.							
3. From: See Attached Schedule A To: See Attached Schedule A							
The document was recorded in the United States Patent and Trademark Office at Reel Schedule a , Frame Schedule a , or for which a copy thereof is attached.							
Note School a Traine Traine School a Traine Sc							
Additional documents in the chain of title are listed on a supplemental sheet(s).							
As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.							
[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]							
The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.							
June 6, 2011							
Signature Date							
President, COO, CFO							
Richard Bagley							
Printed or Typed Name Title							

Attorney Docket No.: ZIPH-009-102

Application #: 10686809 Filing Dt: 10/17/2003 Patent #: 7452910 Issue Dt: 11/18/2008

PCT #: NONE Publication #: US20040171668 Pub Dt: 09/02/2004

Inventors: Bernd Nickel, Gerald Bacher, Thomas Klenner, Thomas Beckers, Peter Emig, Erik

Bruyneel, Gunter Kamp, Kirsten Peters, Jurgen Engel

Title: INDOLYL-3-GLYOXYLIC ACID DERIVATIVES HAVING THERAPEUTICALLY VALUABLE

PROPERTIES

Reel/Frame: 019720 / Received: Recorded: Mailed: Pages: 0655 08/20/2007 08/20/2007 08/21/2007 7

Conveyance: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

Assignors: NICKEL, BERND Exec Dt: 02/16/2000

 BACHER, GERALD
 Exec Dt: 02/16/2000

 KLENNER, THOMAS
 Exec Dt: 02/16/2000

 BECKERS, THOMAS
 Exec Dt: 02/16/2000

 EMIG, PETER
 Exec Dt: 02/16/2000

EXEC DT: 02/10/2000
ENGEL, JURGEN Exec Dt: 02/23/2000
BRUYNEEL, ERIK Exec Dt: 02/18/2000
KAMP, GUNTER Exec Dt: 02/22/2000

PETERS, KIRSTEN Exec Dt: 02/22/2000

Assignee: ASTA MEDICA AKTIENGESELLSCHAFT

AN DER PIKARDIE 10

DRESDEN, GERMANY D-01277

Reel/Frame: 019714 / Received: Recorded: Mailed: Pages: 08/20/2007 08/20/2007 08/21/2007 14

Conveyance: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

Assignor: ASTA MEDICA AKTIENGESELLSCHAFT Exec Dt: 11/05/2001

Assignees: BAXTER HEALTHCARE S.A.

HERTISTRASSE 2

WALLISELLEN, SWITZERLAND 8304
BAXTER INTERNATIONAL INC.

ONE BAXTER PARKWAY
DEERFIELD, ILLINOIS 60015

Reel/Frame: 019714 / Received: Recorded: Mailed: Pages: 08/20/2007 08/21/2007 9

Exec Dt: 07/25/2007

Conveyance: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

Assignors: BAXTER HEALTHCARE S.A. Exec Dt: 07/25/2007

BAXTER INTERNATIONAL, INC.

Assignee: ZIOPHARM ONCOLOGY, INC.

SUITE 300, FLAGSHIP WHARK

197 EIGHTH STREET

CHARLESTOWN, MASSACHUSETTS 02129